THE ROLE OF DEFERROXAMINE IN TREATMENT OF NON ALCOHOLIC FATTY LIVER DISEASE, LIVER- IRON CROSSTALK: HISTOLOGICAL AND BIOCHEMICAL STUDY | ||||
| Egyptian Journal of Histology | ||||
| Articles in Press, Accepted Manuscript, Available Online from 16 May 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejh.2025.361515.2216 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Hoda Mahmoud Al Aasar1; Eman Adel Abdel kader   2; Tarek Ibrahim Abdel Galil 3; Heba Labib2; Mohamed Dief Allah2
| ||||
| 1Department of Anatomy,Kasralainy,faculty of medicine | ||||
| 2Anatomy and Embryology department, Faculty of medicine, Kasr alainy, Cairo university | ||||
| 3Cairo university, faculty of medicine, anatomy department | ||||
| Abstract | ||||
| Background: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver illness; it is intimately concomitant with metabolic comorbidities like obesity, dyslipidemia and insulin resistance. Understanding the pathophysiology of NAFLD is of crucial significance to its actual treatment, as till now there is no definite medical treatment for NAFLD. Iron has been incriminated in the development of NAFLD representing a promising therapeutic goal. Aim of work: The goal was to study iron role in development of NAFLD and to observe Deferoxamine (DFO), as a potent iron chelator, in treatment of NAFLD. Material and Methods: Twenty four adult male albino rats were subdivided into three equal groups as follows; group I (control), group II {high fat diet (HFD)} and group III (HFD- DFO treated). Morphological, biochemical, histo-pathological and immune-histochemical (Caspase-3) assessment were done. Gene expressions of interleukin-6 (IL-6) and hepcidin, as an iron regulating protein, were assayed using real time PCR. Western blotting of ferroportin, main iron exporter, was performed. Histomorphometric analysis and oxidative/antioxidative markers malondialdhyde (MDA)/superoxide dismutase (SOD) were done. Results: DFO injection resulted in amelioration in pathological alterations in the liver tissue regarding steatosis, apoptosis and inflammatory cells infiltration, liver enzymes were decreased. Decrement in hepatic iron content, improvements of lipid profile and insulin resistance were also evaluated. These findings show that the injection of DFO delivers a probable way of slowing NAFLD progress and speed up the cure of liver steatosis and associated comorbidities like Insulin resistance. Conclusion: Deferoxamine can ameliorate the pathological changes in NAFLD and should be regarded as a pharmacological therapy. | ||||
| Keywords | ||||
| NAFLD; Iron; Deferoxamine | ||||
|
Statistics Article View: 171 |
||||
